DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last week citing issues at two of its manufacturing facilities. The warning ...

DexCom Q4 revenue beat at $1.114B, up 8% Y/Y, but EPS missed at $0.45 vs. $0.50 consensus. FY25 guidance reaffirmed with $4.6B revenue target and 21% operating margin. Get stock picks, daily rankings, ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...

Researchers who use Fitabase to capture data from Fitbit and Garmin devices will soon be able to capture a new kind of data: continuous glucose monitoring data from Dexcom products. The ability to ...

Investors have been bearish on DexCom's numbers all this past year. The opportunity in diabetes care, however, remains significant in the long run. The launch of glucose monitor Stelo should ...

In a surprising turn of events, shares of Dexcom Inc. (NASDAQ:DXCM) took a nosedive in pre-market trading following the company’s decision to lower its full-year sales forecast for glucose monitoring ...